# Study in Advanced Solid Tumors

> **NCT01099358** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 47 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** 5 - Fluorouracil

## Key facts

- **NCT ID:** NCT01099358
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2015-10
- **Final completion:** 2016-05
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01099358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01099358, "Study in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01099358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*